Sun Pharma Inds. Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue growth in the latest quarter increased by 15%, indicating robust demand in key markets.
Operating margin improved by 3%, showcasing enhanced operational efficiency compared to previous quarters.
R&D expenditure increased significantly, reflecting a commitment to innovation and long-term growth.

NEGATIVES

Net profit declined by 4% in the latest quarter, diverging from the growth trend seen in prior quarters.
Debt-to-equity ratio worsened slightly, raising concerns about financial leverage and risk.
Inventory levels increased by 10%, suggesting potential issues with overproduction or demand forecasting.

Field	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue	10,930.70	11,940.80	12,192.41	12,380.70	11,982.90	12,652.75	13,291.39	13,675.46	12,958.84	13,851.40
Expenses	8,128.54	8,611.11	9,013.03	9,028.43	8,947.75	9,045.13	9,480.52	9,666.44	9,533.99	9,778.78
Operating Profit	2,802.16	3,329.69	3,179.38	3,352.27	3,035.15	3,607.62	3,810.87	4,009.02	3,424.85	4,072.62
Other Income	373.28	206.48	293.61	374.76	605.94	532.55	482.09	465.62	904.11	693.50
Interest	92.74	80.88	49.29	34.73	73.57	61.54	69.17	51.51	49.14	74.80
Depreciation	671.53	651.32	632.82	622.14	650.36	655.13	625.91	630.56	663.79	700.55
Profit Before Tax	2,205.81	2,473.75	2,775.20	2,992.86	2,807.67	3,412.76	3,604.54	3,471.84	3,247.64	3,163.02
Tax	222.91	468.10	390.10	432.32	148.93	552.25	567.21	558.86	1,093.71	870.15
Net Profit	1,982.90	2,005.65	2,385.10	2,560.54	2,658.74	2,860.51	3,037.33	2,912.98	2,153.93	2,292.87
Eps in Rs	8.30	8.40	9.90	10.50	11.10	11.80	12.70	12.10	9	9.50